Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.
Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L, Reiniger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F. Villa C, et al. Among authors: lania a. Virchows Arch. 2019 Dec;475(6):687-692. doi: 10.1007/s00428-019-02655-0. Epub 2019 Oct 2. Virchows Arch. 2019. PMID: 31578606 Review.
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S, Peri A, Baglioni S, Fustini MF, Pigliaru F, Monte PD, Borretta G, Ambrosi B, Jaffrain-Rea ML, Gasperi M, Brogioni S, Cannavò S, Mantovani G, Beck-Peccoz P, Lania A, Spada A. Filopanti M, et al. Among authors: lania a. Pharmacogenomics J. 2008 Oct;8(5):357-63. doi: 10.1038/tpj.2008.1. Epub 2008 Mar 11. Pharmacogenomics J. 2008. PMID: 18332900
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion.
Trivellin G, Daly AF, Hernández-Ramírez LC, Araldi E, Tatsi C, Dale RK, Fridell G, Mittal A, Faucz FR, Iben JR, Li T, Vitali E, Stojilkovic SS, Kamenicky P, Villa C, Baussart B, Chittiboina P, Toro C, Gahl WA, Eugster EA, Naves LA, Jaffrain-Rea ML, de Herder WW, Neggers SJ, Petrossians P, Beckers A, Lania AG, Mains RE, Eipper BA, Stratakis CA. Trivellin G, et al. Among authors: lania ag. Front Endocrinol (Lausanne). 2023 Jun 14;14:1166076. doi: 10.3389/fendo.2023.1166076. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37388215 Free PMC article.
Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy.
Lazzeri M, Duga S, Azzolini E, Fasulo V, Buffi N, Saita A, Lughezzani G, Paraboschi EM, Hurle R, Nobili A, Cecconi M, Guazzoni G, Casale P, Asselta R; Humanitas COVID-19 Task Force, The Humanitas Gavazzeni COVID-19 Task Force. Lazzeri M, et al. Minerva Urol Nephrol. 2022 Feb;74(1):77-84. doi: 10.23736/S2724-6051.20.04081-3. Epub 2021 Jan 13. Minerva Urol Nephrol. 2022. PMID: 33439572 Free article.
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F, Esposito E, Treppiedi D, Catalano R, Marra G, Di Muro G, Barbieri AM, Locatelli M, Lania AG, Mangone A, Spada A, Arosio M, Peverelli E, Mantovani G. Mangili F, et al. Among authors: lania ag. Front Endocrinol (Lausanne). 2022 Jun 3;13:867822. doi: 10.3389/fendo.2022.867822. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35721701 Free PMC article.
287 results